Bio Campus News Today

INCHEON, South Korea, April 24, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO),

- Samsung Biologics to develop and manufacture antibody for ADC candidate - Latest deal comes as Samsung Biologics is on track to complete construction of an ADC facility this year INCHEON, South Korea, Feb. 7, 2024

/PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today presented its 2024 business...

SAN FRANCISCO – Samsung Biologics, the biotech arm of Samsung Group, is seeking to further consolidate its leadership in the soaring contract manufacturing and development market by outpacing rivals in terms of production capacity. "I am aware of the market's post-pandemic oversupply concerns. However, considering the continual rise in our orders, the choice to expand production capacity is deemed ess...

SAN FRANCISCO – Samsung Biologics, the biotech arm of Samsung Group, is seeking to further consolidate its leadership in the soaring contract manufacturing and development market by outpacing rivals in terms of production capacity. "I am aware of the market's post-pandemic oversupply concerns. However, considering the continual rise in our orders, the choice to expand production capacity is deemed ess...

Samsung Biologics is investing in new production facilities and exploring opportunities in new business areas after milestone revenue in the third quarter. "Now is the time for us to prepare for the next phase with a new modality and overwhelming production capability," Samsung Biologics CEO John Rim said during a press conference on Wednesday, held in Barcelona in line with the company’s participatio...

/PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the worlds leading contract development and manufacturing organization (CDMO), today announced financial...

Samsung Biologics, the biotech arm of Koreas Samsung Group, said Wednesday it will open a new biomedicine production facility in April 2025 as part of its plans to deal with rising contract manufacturing demand.

In a wide open space just a few minutes away from Samsung Biologics’ first Bio Campus in Songdo, Incheon, the company’s Plant 5 is under construction. Prefabricated concrete-based frames implemented in a neatly controlled construction environment provide a glimpse into the company's new facility, which would further consolidate the firm’s leadership as the world’s largest contract develop...

In a wide open space just a few minutes away from Samsung Biologics’ first Bio Campus in Songdo, Incheon, the company’s Plant 5 is under construction. Prefabricated concrete-based frames implemented in a neatly controlled construction environment provide a glimpse into the company's new facility, which would further consolidate the firm’s leadership as the world’s largest contract develop...